- Home
- JELD vs CNTB Comparison
JELD vs CNTB Comparison
Compare JELD & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | CNTB |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 135.7M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JELD | CNTB |
|---|---|---|
| Price | $1.89 | $2.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.43 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 1.4M | 355.3K |
| Earning Date | 05-04-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $1.23 |
| 52 Week High | $6.98 | $3.82 |
Technical Indicators
Market Signals| Indicator | JELD | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 74.17 | 51.30 |
| Support Level | $1.64 | $1.98 |
| Resistance Level | $2.06 | $2.64 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 100.00 | 86.44 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.